Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Universitéde Strasbourg

Eli Lilly and Company

Societe Civile Bioprojet

Societe Civile Brioprojet

André Mann

Camille-Georges Wermuth

Martial Ruat

Maurizio Taddei

Pierre Sokoloff

Hélène Faure

Fabrice Garrido

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Fabrizio Manetti

Antonio Solinas

Angèle Schoenfelder

Angele Schoenfelder

Elisabeth Traiffort

Hermine Roudaut

Concepcion Pedregal Tercero

Darryle D Schoepp

Stephan Schann

Jesus Ezquerra Carrera

Bruno Giros

Almudena Rubio Esteban

Didier Rognan

Tatiana Gorojankina

Pascal Bousquet

Marie-Pascale Martres

Nathalie Niederhoffer

Jean Daniel Ehrhardt

Angéle Schoenfelder

Catherine Pilon

Lyne Fellmann

Vincent Gasparik

Hugues Greney

Lucile Hoch

Mohamed Hadjeri

Novel amino-pyrrolinic derivatives, their pharmacologically acceptable salts and use thereof in the prevention and/or treatment of metabolic syndrome.

Amino-pyrroline derivatives, and use thereof in the prevention and/or treatment of metabolic syndrome

The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.

N-acylthiourea and N-acylurea inhibitors of the Hedgehog protein signalling pathway

The present invention relates to compounds which are quinolinone derivatives of general formula (I) capable of modulating the activity, in particular of inducing the differentiation, of stem and progenitor cells; these compounds are of use in the treatment of disorders related to a stem differentiation defect; the invention also relates to novel compounds among these quinolinone derivatives and to pharmaceutical compositions containing the same. 

Quinolinone derivatives

The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I). The invention also relates to a method for radio-marking compounds having formula (I), the marked compounds, and the use of the compounds as research tools, and method for screening and/or identifying ligands in the Smoothened receptor (Smo) binding sites, methods for identifying agonists and antagonists of the Smoothened receptor, and a method for identifying cells.

Compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications

The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.

Acyl guanidine derivatives modulating the hedgehog protein signaling pathway

The invention relates to 3,4-dihydro-2-naphthamide derivatives of formula (I), pharmaceutical compositions containing them and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor for the treatment of neuropsychological disorders.

3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands

The invention relates to 2-naphthamide derivatives, in the form of bases or of salts, corresponding to the following general formula (I): ##STR1## in which: the Z-Y entity represents an N--CH.sub.2, C.dbd.CH or CH--CH.sub.2 group;

2-naphthamide derivatives and their therapeutic applications

The invention related to 2-naphthamide derivatives, in the form of bases or of salts, corresponding to the following general formula (I): ##STR1## in which: the Z--Y entity represents an N--CH.sub.2, C.dbd.CH or CH--CH.sub.2 group;

2-Naphthamide derivatives and their therapeutic applications

Disclosed herein is a method of treating a disease of the central nervous system with a compound of the formula ##STR1## in which m is 0, 1 or 2, n and q are each 0 or 1 to 5, and p is 0 or 1, X is --CO.sub.2 H or tetrazolyl,

Pharmaceutical compounds for the treatment of CNS diseases

The new naphthamide derivatives according to the invention are characterized in that they correspond to the general formula (I), ##STR1## where X: represents either a hydrogen atom, or a chlorine or bromine atom, or an amino or aminoalkyl group, an aminosulphamoyl group, a sulphur-containing group such as thiocyanate, alkylthio, alkylsulphinyl or alkylsulphonyl, or a methoxy group, or a nitro group, or a cyano group, or an electron-attracting group;

Naphthamide derivatives

Growing community of inventors

Ostwald, France

André Mann